glp-1 and alcohol receptor agonists show promise in treating substance use disorders GLP-1s tied to lower alcohol

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

Read more at straitstimes.com

Some employers choose to exclude GLP-1 drugs from employer-sponsored health plans

Depression concerns among semaglutide users have sparked important clinical conversations

This Willow review outlines pricing structure, complaint patterns, legitimacy signals, and how the GLP-1 telehealth program operates before enrollment.

Metabolic Support from Multi-Active Ingredients: RevionLabs GLP-1 Support Drink Mix provides metabolic support through well-studied ingredients that include green coffee bean extract, taurine, ginseng, and green tea extract